MedTrace Logo

Evaluate Different Extended-release (ER) Tablets/Capsules of AZD1305

NCT00689403 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2010-12-03

No results posted yet for this study

Summary

To study the properties of different tablets/capsules of AZD1305 in healthy male volunteers.

Conditions

  • Healthy

Interventions

DRUG

AZD1305

Extended release capsules, oral single doses

DRUG

AZD1305

Extended release capsules, oral single doses

Sponsors & Collaborators

Principal Investigators

  • Helen Lunde, MD · AstraZeneca R&D, Mölndal, Sweden

  • Daniel Bradford, MD, MA, MBBS, DCPSA · PAREXEL Clinical Pharmacology Research UnitHarrow, United Kingdom

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2008-07-31
Completion
2008-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00689403 on ClinicalTrials.gov